Importantly, these investigators found that reducing the inflammatory markers, CRP and IL-6 (and likely other pro-inflammatory proteins) with canakinumab (a monoclonal antibody against IL-1β) dramatically reduced the incidence of lung cancer in these patients17. Here, CRP is linked to lung carcinoma.